Pavel Strop

USPTO Granted Patents = 27 (Patent Applications = 16)

CIPO Patents = 10 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 6.3

ph-index = 7

Forward Citations = 209(Granted Patents)

Company Filing History:

Rinat Neuroscience Corporation

patents

2 out of 3,681

Bristol-myers Squibb Compnay

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12290570 - Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses (2025-05-06),

2. 11993625 - Calicheamicin derivatives and antibody drug conjugates thereof (2024-05-28),

3. 11814435 - Therapeutic antibodies and their uses (2023-11-14),

4. 11602525 - Antibody-drug conjugates with high drug loading (2023-03-14),

5. 11390689 - Heterodimeric proteins and methods for producing and purifying them (2022-07-19),

6. 11242393 - Antibodies against MICA and/or MICB and uses thereof (2022-02-08),

7. 11155630 - Therapeutic antibodies and their uses (2021-10-26),

8. 11091544 - Antibodies specific for Trop-2 and their uses (2021-08-17),

9. 10967068 - Stability-modulating linkers for use with antibody drug conjugates (2021-04-06),

10. 10941216 - Engineered polypeptide conjugates and methods for making thereof using transglutaminase (2021-03-09),

11. 10842881 - Engineered polypeptide conjugates using transglutaminase (2020-11-24),

12. 10793635 - Therapeutic antibodies and their uses (2020-10-06),

13. 10689458 - Site specific HER2 antibody drug conjugates (2020-06-23),

14. 10195289 - Engineered polypeptide conjugates using transglutaminase (2019-02-05),

15. 10138303 - Heterodimeric proteins and methods for producing and purifying them (2018-11-27),

Title: Innovations by Pavel Strop: A Path to Advancing Cancer Treatments

Introduction

Pavel Strop, a distinguished inventor based in San Mateo, California, has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 26 patents, his work focuses on developing innovative therapies, particularly in cancer treatment.

Latest Patents

Among his recent advancements, Strop has developed novel calicheamicin derivatives designed for use as payloads in antibody-drug conjugates (ADCs). This invention aims to enhance the effectiveness of treatments targeting cancerous cells. In addition, his patent on therapeutic antibodies highlights the creation of full-length antibodies and binding fragments that specifically engage with B-Cell Maturation Antigen (BCMA) and Cluster of Differentiation 3 (CD3). Additionally, his work includes developing bispecific antibodies that can target both CD3 and tumor cell antigens, further broadening therapeutic applications for cancer and autoimmune diseases.

Career Highlights

Strop's innovative journey includes key roles at prominent corporations, including Pfizer Corporation and Rinat Neuroscience Corporation. His expertise in biochemistry and pharmacology has been instrumental in advancing scientific understanding and therapeutic interventions.

Collaborations

Throughout his career, Pavel has collaborated with notable colleagues, including Arvind Rajpal and Magdalena Grazyna Dorywalska. These partnerships have cultivated an environment of creativity and innovation, enabling impactful research and patent generation in the biopharmaceutical sector.

Conclusion

Pavel Strop's contributions to the field of pharmaceutical innovations emphasize his commitment to improving healthcare outcomes through advanced therapies. His patents not only reflect his inventive mindset but also represent significant strides toward tackling complex diseases such as cancer. As he continues to explore new avenues of research, Strop remains a key figure in the pursuit of medical innovation.

This text is generated by artificial intelligence and may not be accurate.